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1. Temporal profile of Map2 immunostaining in the hippocampus  
 after status epilepticus (SE). A, shows a representative image of  
 the Map2 staining (brown) from a control hippocampus with a high  
 magnification image of the CA1 area (boxed). B-H show  
 representative hippocampal images with high magnification of  
 boxed CA1 areas at different time points after an episode of SE  
 (B, 4 hrs; C, 1 day (d); D, 3d; E-F, 14d; H, 35d). A representative  
 image of a hippocampus from a rat that was given pilocarpine but  
 failed to develop SE (pilo-non SE; Pilo in graphs) is shown in G. I,  
 shows the densitometry analysis as relative mean pixel intensity  
 for the different hippocampal sub-regions CA1 pyramidal cell layer  
 (pcl) and stratum radiatum (sr), CA3 pcl and sr, and the molecular  
 layer (ml) of the dentate gyrus (DG). Note that significant  
 differences in the intensity of Map2 immunoreactivity are evident  
 within the CA1 region between the control group and 1-35d post- 
 SE groups.  Data are shown as mean ± standard error of the  
 mean. *, p < 0.05; **, p < 0.01; ***, p < 0.001 compared to the  
 control group. #, p < 0.05, comparison between 14d and 35d  
 groups (n = 3-9/group) (shown inside the bar graphs).  ANOVA  
 with Tukey’s post hoc test . . . . . . . . . . . . . . . .  28 
 
2. Temporal profile of changes in spine density in hippocampal CA1  
 cells after status epilepticus (SE). A-D, shows representative  
 images of golgi impregnated hippocampal dendrites from a control  
 rat (A) and at different time points following an episode of SE (B,  
 3 days (d); C, 14d; D, 35d). E, shows representative images of 20  
 µm sections of CA1 dendritic branches from a control, and 3-, 14-  
 and 35- days post-SE. F, shows the quantitative analysis of spine  
 density in all groups. Data are shown as mean ± standard error of  
 the mean. *, p < 0.05; ***, p < 0.001 compared to the control group.  
 N numbers of dendritic branches quantified per animal are shown  
 inside the bar graphs.  ANOVA with Tukey’s post hoc test . . . .  31 
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3. Temporal profile of IBA1 immunostaining in the hippocampus after  
 status epilepticus (SE). A-H, show representative images of the  
 IBA1 staining (brown) from a control hippocampus (A) and from  
 hippocampi collected at different time points after an episode of  
 SE (B, 4 hrs; C, 1 day (d); D, 3d; E-F, 14d; H, 35d). A  
 representative hippocampus from a rat that was given pilocarpine  
 but failed to develop SE (pilo-non SE; Pilo in graphs) is shown in  
 G. Right panels show high magnification images of boxed CA1,  
 CA3, and the hilus of the dentate gyrus (DG). High magnification  
 images with IBA1-labeled microglia (arrows) are also shown.  
 Nissl stained cellular nuclei are shown in blue. Abbreviations: pcl,  
 pyramidal cell layer; sr, stratum radiatum; slm, stratum  
 lacunosum-moleculare. I, shows the densitometry analysis as  
 relative mean pixel intensity for the different hippocampal sub- 
 regions CA1, CA3, and hilus. Significant differences in the  
 intensity of IBA1-stained microglia are evident in the CA1, CA3,  
 and hilar regions at 4 hrs and 14d after SE compared to the  
 control group. Data are shown as mean ± standard error of the  
 mean. *, p < 0.05; **, p < 0.01; ***, p < 0.001 compared to the  
 control group. #, p < 0.05, comparison between 14d and 35d  
 groups (n = 4-11/group) (shown inside the bar graphs).   
 ANOVA with Tukey’s post hoc test . . . . . . . . . . . . .  34 
 
4. Temporal profile of C1q immunostaining in the hippocampus after  
 status epilepticus (SE). A-E, show representative images of the  
 C1q staining (brown) from a control hippocampus (A) and from 
 hippocampi collected at different time points after an episode of  
 SE (B, 3 days (d); C, 14d; D, 23d; E, 35d). Nissl stained cellular  
 nuclei are shown in blue. F, shows the densitometry analysis as  
 relative mean pixel intensity for hippocampal subregions CA1  
 pyramidal cell layer (pcl) and stratum radiatum (sr). Significant  
 differences in the intensity of C1q immunoreactivity are evident  
 in the CA1 sr subregion at 14d after SE compared to the control  
 group. G, shows colocalization of C1q (green) with Map2 (red),  
 in control CA1 hippocampi and in hippocampi from 3-, and 14- 
 days after SE. Note that due to the low intensity of Map2 IR at  
 14 days, potential colocalization with C1q is inconclusive. Data  
 are shown as mean +/- standard error of the mean. N numbers  
 of animals used are shown inside the bar graphs.  *, p < 0.05.  
 ANOVA with Tukey’s post hoc test . . . . . . . . . . . . .  38 
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5. Temporal profile of C3 protein levels and cleavage after an  
 episode of status epilepticus (SE). A, shows representative  
 western blot of C3 in hippocampi dissected at different time- 
 points (14-, and 25-, and 35-days) after SE loaded next to  
 respective age-matched controls. Different bands represent  
 cleavage products of C3: C3bα, C3bβ, and iC3b. Below is the  
 same blot immunoblotted with actin, the loading control. B,  
 shows the densitometry analysis as percent pixel intensity for  
 C3bα, C3bβ (C), and iC3b (D). All experimental time points were  
 compared to their corresponding controls. Data are shown as  
 mean +/- standard error of the mean.  N numbers of animals  
 used are shown inside bar graphs.  *, p < 0.05, #, p = 0.06.  
 Unpaired t test. ANOVA with Tukey’s post hoc test . . . . . . .  41 
 
6. Experimental paradigm for treatment with C1-esterase inhibitor  
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 (brown) from a control brain. B-D, show representative brain  
 images at different time points after an episode of SE, next to an  
 image from matching time-points after SE with C1-Inh treatment  
 (B, 3 days (d); C, 14d; D, 25d). E, shows the densitometry  
 analysis of Map2 immunoreactivity (IR) as percent control pixel  
 intensity for the hippocampal CA1 region. Note that Map2 IR is  
 lowest at 14d after SE, and is not altered with C1-Inh treatment  
 compared to SE. Data are shown as mean ± standard error of the  
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11. Treatment with C1-esterase inhibitor (C1-Inh) does not attenuate  
 recognition memory in rats subjected to status epilepticus (SE).  
 The novel object recognition (NOR) test was used to measure  
 recognition memory after SE and after SE with C1-Inh treatment.  
 A, shows the percent exploration time of each object during the  
 first trial. None of the treatment groups showed preference for  
 either the right or the left object. B, shows the percent exploration  
 time during the second trial. Note that only the control animals  
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 of the familiar object. Data are shown as mean +/- standard error  
 of the mean. *, p < 0.05 (n = 11-21/group). N numbers of animals  
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Status epilepticus (SE) triggers pathological changes to hippocampal dendrites 
that may promote epileptogenesis. The microtubule associated protein 2 
(Map2) helps stabilize microtubules of the dendritic cytoskeleton. Recently, we 
reported a substantial decline in Map2 that coincided with robust microglia 
accumulation in the CA1 hippocampal region after an episode of SE. A spatial 
correlation between Map2 loss and reactive microglia was also reported in 
human cortex from refractory epilepsy. New evidence supports that microglia 
are guided by proteins of the classical complement pathway (C1q and C3) to 
prune dendritic structures.  Furthermore, components of complement have 
been shown to be upregulated in human and experimental epilepsy. Thus, to 
identify a potential role of the classical complement pathway in SE-induced 
Map2 and microglial changes, we characterized the spatiotemporal profile of 
these events. We used immunohistochemistry to determine the distribution of 
Map2 and the microglia marker IBA1 in the hippocampus after pilocarpine-
induced SE from 4 hours to 35 days. We found a decline in Map2 
x 
immunoreactivity in the CA1 area that reached minimal levels at 14 days post-
SE and partially increased thereafter. In contrast, maximal microglia 
accumulation occurred in the CA1 area at 14 days post-SE. We then mapped 
the spatiotemporal profile of C1q using immunohistochemistry at 3-35 days 
after SE, where substantial Map2 and microglial alterations were observed. We 
used western blot to determine the levels of C3 and its cleavage products. C1q 
and C3 were both increased in the hippocampus at 14 days after SE, when 
Map2 and microglia changes were most profound. Our data indicate that SE-
induced Map2 and microglial changes parallel each other’s spatiotemporal 
profiles. These findings also suggest a potential role for the classical 
complement pathway in SE-induced Map2-microglial interactions. 
Cognitive deficits are often associated with epilepsy and experimental 
models of SE and TLE, particularly because the hippocampus is often 
vulnerable to injury in TLE. To test the potential role of the classical 
complement pathway in SE-induced hippocampal injury and hippocampal-
dependent cognitive deficits, we used a pharmacological approach to block the 
classical complement pathway with the C1 esterase inhibitor (C1-Inh). This 
drug was given at 4-, 24-, and 48-hours after SE. Tissue was collected at 3-, 
14-, 25-, and 35-days after SE and a separate cohort of animals were used to 
test the effects of C1-Inh on cognitive performance using the novel object 
recognition (NOR) and the Barnes maze (BM) tests. We found that C1-Inh had 
no effect on hippocampal Map2 loss after SE when compared with hippocampi 
from the SE groups. Furthermore, microgliosis was exacerbated with C1-Inh 
xi 
treatment, with a significant increase lasting from 3 days to 35 days after SE. 
We replicated previous studies showing a deficit in the NOR and BM tests after 
SE. However, C1-Inh treatment did not attenuate these deficits, and in fact 
exacerbated the effects in the BM. Taken together, these data support the idea 
that the classical complement pathway may play a role in epileptogenesis, 
inflammation, and cognitive deficits, but more experiments are needed to 
understand what the specific proteins and mechanisms are involved. Future 













Epilepsy: A Clinical Problem 
Epilepsy is one of the most common neurological disorders, affecting 65 
million people world-wide (Thurman et al., 2011). According to the Epilepsy 
Foundation, one in 26 people will develop epilepsy in their lifetime, and one 
third of people with epilepsy do not respond to currently available anti-epileptic 
drugs (AEDs). Epilepsy is a seizure disorder which consists of spontaneous 
recurrent seizures (SRS) (Scharfman, 2007). Seizures are characterized by 
aberrant synchronous neuronal activity consisting of high amplitude and high 
frequency (200-500 Hz) spikes (Scharfman, 2014). The cause of this increase 
neuronal activity is thought to be an imbalance of excitatory and inhibitory 
synapses (Badawy, Harvey, & Macdonell, 2009), but the underlying 
mechanisms are poorly understood.  
Epilepsy is considered a spectrum disorder. There are many different 
types of epilepsies, varying in number of occurrences, location, severity, and 
onset of seizures (Jacobs et al., 2009). There are over a dozen types of 
epilepsy syndromes; some stem from genetics and some are acquired 
mechanisms. Several single gene mutations have been identified in epilepsy. 
However, the majority of epilepsy disorders involve far more complex 
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inheritance, and the development of spontaneous seizures is most likely due to 
an interaction of several gene mutations and the environment (Berkovic, 
Mulley, Scheffer, & Petrou, 2006). Genetic disorders associated with seizures 
include Fragile X Syndrome, Angelman’s Syndrome, and generalized epilepsy 
with febrile seizures plus, among others. Mutations of genes that code for 
voltage gated potassium, sodium, and chloride channels have been shown to 
be involved in epilepsies, as they are responsible for altering membrane 
excitability (Steinlein, 2004). Although it is widely known as a seizure disorder, 
people with epilepsy have an increased risk of several comorbidities including 
cognitive impairments, anxiety, and autism, among others (Stafstrom, 2014). 
Temporal Lobe Epilepsy 
Temporal lobe epilepsy (TLE) is a form of epilepsy that is defined by the 
occurrence of at least two unprovoked epileptic seizures over a period of at 
least 24 hours, and can be genetic or acquired (Wiebe, 2000). Medial temporal 
lobe epilepsy (mTLE) originates in the amygdalo-hippocampal area and is 
often resolved with surgery, when surgery is an option, because most cases 
are refractory to pharmaceutical interventions (Téllez-Zenteno & Hernández-
Ronquillo, 2012). Individuals with pharmacoresistant (intractable) mTLE report 
poorer quality of life; including increased depression, social isolation, and 
unemployment (Alonso-Vanegas et al., 2013). People with intractable mTLE 
sometimes are not candidates for surgery because, for instance, their seizures 
originate from more than one area in the brain. When intractable mTLE cannot 
be resolved with surgery, little or no treatment options remain. TLE can be the 
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result of genetics, developmental malformation, or brain injury including events 
such as traumatic brain injury, stroke, and prolonged continuous seizures due 
to fever and infections among others (acquired epilepsy) (Aird, Venturini, & 
Spielman, 1967; Neppe, 1981). mTLE is often associated with injury to the 
hippocampus which results in hippocampal sclerosis and neurodegeneration, 
and synaptic and network remodeling (Rao, Hattiangady, Reddy, & Shetty, 
2006). Some experimental models of mTLE suggest that neurodegeneration 
may be a contributor to the generation of an epileptic brain, while others 
suggest that it is a consequence of dendritic and synaptic remodeling within the 
hippocampal network (Rao et al., 2006). However, the mechanisms that deeply 
impact hippocampal neuronal and dendritic stability and neuronal 
hyperexcitability in TLE remain elusive. 
Epileptogenesis 
As mentioned above, events such as traumatic brain injury, fever, 
infections, or stroke can precipitate a long-lasting continuous seizure (status 
epilepticus; SE). SE is diagnosed when the seizures become prolonged and 
continue for 15 minutes or more, or if there is a period of intermittent seizures 
without regaining consciousness for the same amount of time (Chapman, 
Smith, & Hirsch, 2001; Nair, Kalita, & Misra, 2011). Extensive evidence 
suggest that a single episode of SE is sufficient to turn a normal brain into an 
epileptic brain (Curia, Longo, Biagini, Jones, & Avoli, 2008), and often mTLE 
and cognitive comorbidities follow (Brewster et al., 2013; Cavalheiro et al., 
1991; Leite, Bortolotto, & Cavalheiro, 1990; Nair et al., 2011). The transition 
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period from a normal brain to an epileptic brain is known as epileptogenesis. 
This phenomenon has been observed in humans and in experimental models 
such as the pilocarpine model of SE and acquired mTLE, in which 
epileptogenesis occurs during a seizure-free “latent period” that starts after an 
initial SE episode (Jefferys, 2010). 
Neuronal injury associated with an episode of SE and subsequent 
seizures that further alter neuronal networks can contribute to an even more 
hyper-excitable circuitry and SRS. SE often precipitates damage to 
hippocampal neuronal and dendritic elements (do Nascimento et al., 2012; Rao 
et al., 2006; Swann, Al-Noori, Jiang, & Lee, 2000). During the latent period 
after SE, there are changes in connectivity, particularly in the CA1 region of the 
hippocampal formation (Brewster et al., 2013; Jung et al., 2009; Rao et al., 
2006; Schartz et al., 2016). Also, studies using electron microscopy have 
shown that after seizures, axons of the dentate gyrus (DG) in the hippocampus 
expand and innervate dendrites in novel areas, and this re-organization is 
unique to epileptic brains (Scharfman, 2007).  Furthermore, it has been 
suggested that neuronal injury due to seizures, accompanied by the release of 
inflammatory signals (e.g., TNF-alpha, IL-1beta), triggers microglia activation 
and subsequent inflammation and phagocytosis of these stressed neurons 
(Andersson, Perry, & Gordon, 1991; Borges et al., 2003; Eyo, Murugan, & Wu, 
2016; Eyo et al., 2014; Turrin & Rivest, 2004; Vezzani et al., 1999). Loss of 
hippocampal neurons may promote formation of excitatory axonal pathways, 
and this excitement may be exacerbated by a loss of inhibitory pathways 
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(Dingledine, Varvel, & Dudek, 2014). Evidence suggests a role of microglia in 
the development of epilepsy. During the latent period, there is an accumulation 
of microglia in the hippocampus paired with a loss of neuronal and dendritic 
markers (Rao et al., 2006; Schartz et al., 2016). Pre-treatment as well as 
treatment up to two weeks after SE with a potent immunosuppressant 
attenuates neuronal and dendritic alterations associated with SE, as well as 
cognitive impairments and may attenuate the occurrence of SRS after the 
latent period (Brewster et al., 2013; Guo et al., 2016; Huang et al., 2010; Wang 
et al., 2015; Zeng, Rensing, & Wong, 2009). Taken together these studies 
suggest a role for immune cells and neuroinflammation in the dendritic 
pathology associated with SE and epilepsy.  
Cognitive and Behavioral Deficits in SE and mTLE 
Individuals with severe mTLE can have decreased cognitive function 
(Abrahams et al., 1999; Guerreiro, Jones-Gotman, Andermann, Bastos, & 
Cendes, 2001), which may contribute to self-reported poor quality of life. In the 
pilocarpine model of acquired TLE, rats display similar cognitive dysfunction 
(Brewster et al., 2013; Chauviere et al., 2009; Hort, Broźek, Mareš, Langmeier, 
& Komárek, 1999; Pearson, Schulz, & Patel, 2014). The hippocampus has 
been implicated as the area of the brain responsible for integrating information 
into long term memory, as well as for spatial memory (Schenk & Morris, 1985; 
Scoville & Milner, 1957). As early as 1 week after SE, there is a decrease in 
the immunoreactivity (IR) to neuronal marker NeuN and dendritic marker 
microtubule associated protein-2 (Map2) in the CA1 area of the hippocampus 
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in animal models (Rao et al., 2006; Schartz et al., 2016). Using behavioral tests 
that assess hippocampal-dependent memory tasks, such as novel object 
recognition (NOR) and Morris water maze (MWM), it has been established that 
the pilocarpine model of SE results in a long-lasting deficit in retention of 
information, detectable as early as 5 days after SE (Brewster et al., 2013; 
Pearson et al., 2014). Previous studies using the NOR test in rats that have 
undergone SE established a deficit of SE rats in distinguishing between familiar 
and novel objects after a 24 hour retention period. Tests like the MWM also 
show a deficit in spatial memory in pilocarpine treated rodents, however this 
test may not be appropriate for this model because of the physical aspects of 
epilepsy (e.g. unprovoked seizures) (Brewster et al., 2013; Murphy, 2013). In 
the MWM, rodents are placed in a pool of opaque water and must find a hidden 
platform guided by visual cues placed around the testing room. This test is 
effective, but could potentially be dangerous in an epileptic rodent. At the time 
point of testing, some rats are exhibiting spontaneous seizures, which could be 
fatal if it occurs during the MWM. An alternative to the MWM is the Barnes 
maze (BM). This test uses the same rationale and general design as the MWM, 
but eliminates the water. Instead, rats are placed on a circular platform with 
one escape hole that the rat has to find using spatial cues placed around the 
room. Both reward (food) and anxiogenic conditions (bright light or loud noise) 
can be used to make the rodent enter the escape hole. Previous studies have 
found deficits in this test in a mouse model of epilepsy (Levin, Serrano, & 
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Dingledine, 2012). Therefore, the BM test is an appropriate measure of spatial 
memory in models of SE and acquired epilepsy. 
Specific Evidence for Dendritic/Neuronal Damage 
Dendrites make up most of a neuron’s surface area, where numerous 
neurotransmitter receptors and ion channels play a critical role in shaping the 
response to synaptic inputs under physiological conditions and in epilepsy. SE 
is associated with altered dendritic stability of hippocampal neurons. For 
instance, dendritic size and number of branches have repeatedly been 
reported to decrease in epilepsy (Swann et al., 2000; Wong, 2005). Map2 is 
critical for microtubule assembly and thereby for structural stability of the 
dendritic cytoskeleton (Dehmelt & Halpain, 2004). Pharmaco-genetic 
manipulations of Map2 protein have elucidated its roles in intracellular 
trafficking, dendritic plasticity, stability and spine growth (Harada, Teng, Takei, 
Oguchi, & Hirokawa, 2002). Seizures result in altered levels and distribution of 
Map-2 in the hippocampus (Ballough et al., 1995; Dachet et al., 2015; Jalava, 
Lopez-Picon, Kukko-Lukjanov, & Holopainen, 2007; Schartz et al., 2016). 
Evidence suggest that seizures are associated with decreases of Map2 IR 
(Ballough et al., 1995), a clear indicator of brain damage. Dendritic alterations 
have been found in both clinical cases and animal models of epilepsy 
(Brewster et al., 2013; Dachet et al., 2015; Ma, Ramachandran, Ford, Parada, 
& Prince, 2013; Schartz et al., 2016).  
In some instances, the loss of Map2 may be directly associated with 
neuronal loss which can occur in the CA1 hippocampal region originating from 
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chronic intractable epilepsy. In parallel, immunostaining of such tissue has 
revealed accumulation of astrocytes and microglia in the epileptic focus 
(Aronica et al., 2007; Dachet et al., 2015). High magnification 
immunofluorescence has revealed that after an episode of SE, there is a 
decrease in dendritic marker Map2, and microglial marker (IBA1) makes more 
contacts with dendrites in the hippocampus when compared with control 
(Brewster et al., 2013). Loss of Map2 occurring in parallel with accumulation of 
microglia has also been observed in tissue resected from the brains of patients 
with long-standing epilepsy (Dachet et al., 2015). 
Role of Microglia 
Microglia are the resident immune cells of the central nervous system 
and modulate neuroinflammatory responses associated with injury and disease 
(Kettenmann, Hanisch, Noda, & Verkhratsky, 2011). Pathological 
circumstances trigger microglia to infiltrate, accumulate, and to develop 
inflammatory and phagocytic phenotypes that include changes in their 
morphological appearance from highly ramified to hypertrophied/amoeboid, 
and the production and release of inflammatory cytokines, chemokines, and 
trophic factors (Kettenmann et al., 2011). The presence of microglia with 
hypertrophied or amoeboid morphologies expressing a number of inflammatory 
proteins is a feature often seen in hippocampal tissue resected from individuals 
with intractable temporal lobe epilepsy and widely observed in association with 
seizures in experimental animal models (Vezzani, French, Bartfai, & Baram, 
2011). Immunohistochemical analyses support activation of microglia in all sub 
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regions of the hippocampus (e.g. CA1, CA3, and DG) following SE (Amhaoul et 
al., 2015; Avignone, Ulmann, Levavasseur, Rassendren, & Audinat, 2008; 
Brewster et al., 2013; M. G. De Simoni et al., 2000; Patterson et al., 2015; 
Ravizza et al., 2005; Rizzi et al., 2003; Shapiro, Wang, & Ribak, 2008; A. 
Vezzani & Granata, 2005). Even though little is known about the potential role 
of microglia in the disruption of dendritic stability after SE, evidence suggest 
that microglia and its associated neuroinflammatory and phagocytic properties 
are implicated in neural degeneration along with neuronal structural changes 
that include aberrant dendritic morphology, altered spine densities, synapse 
pruning, and axonal sprouting (Allan & Rothwell, 2003; Eyupoglu, Bechmann, 
& Nitsch, 2003; Horn, Busch, Hawthorne, van Rooijen, & Silver, 2008; 
Richwine et al., 2008; Shapiro, Korn, & Ribak, 2005; Tremblay et al., 2011; 
Yang et al., 2010). Taken together, these studies suggest that microglial cells 
play non-canonical roles in modulating neuronal processes.  
Microglia release neuroprotective substances such as brain derived 
neurotrophic factor (BDNF) and nerve growth factor (NGF), to facilitate neuron 
repair and regrowth (Mirrione & Tsirka, 2011) and promote anti-inflammatory 
responses through phagocytosis of apoptotic cells (Tremblay et al., 2011). 
Additionally, microglia play a role in activity-dependent synaptic remodeling 
(Schafer, Lehrman, & Stevens, 2013). This has been observed in 
developmental synaptic pruning in which microglia eliminate extra synapses to 
allow the remaining synapses to strengthen. Microglia-mediated synaptic 
pruning has also been observed in pathological conditions (Hong et al., 2016; 
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Stephan, Barres, & Stevens, 2012). After facial nerve axotomy, activated 
microglia disconnect the dendrites from axonal terminals (Tremblay et al., 
2011). Microglial activation has been reported following seizures in various 
experimental animal models of epilepsy and in human epileptic tissue (Choi & 
Koh, 2008; Vezzani & Granata, 2005). Models of SE result in significant 
activation of microglia in CA1, CA3, and DG areas of the hippocampus 
(Avignone et al., 2008; Schartz et al., 2016). 
Existing evidence suggest that suppression of reactive microglia in 
models of SE and other neurodegenerative brain injuries is neuroprotective 
(Brewster et al., 2013; Bye et al., 2007; Guo et al., 2016). Administration of an 
immunosuppressant after SE inhibits microglia and reduces cognitive and 
behavioral effects (Brewster et al., 2013). This evidence supports that aberrant 
microglia activity may play a causal role in damage to neuronal and dendritic 
components. However, the underlying mechanisms of microglia-mediated 
injury in epilepsy and after SE remain unclear. Recent evidence indicate that 
microglia interact with spines and eliminate synapses guided by “find me” and 
“eat me” signals sent by proteins of the classical complement cascade 
(Stevens et al., 2007). 
Role of the Classical Complement Pathway 
The complement system has long been known as first responders of the 
innate immune system to pathogens or apoptotic cells. Complement activation 
occurs via the classical, lectin, or alternative pathways. Although each pathway 
is activated by its own distinct activating molecule, all pathways converge on 
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the complement protein C3. The classical complement cascade is activated 
when C1q binds one of its ligands. Once activated, C1q binds to the active 
proteases C1r and C1s to form the C1 complex. The complex then cleaves the 
proteins C4 and C2, the cleavage 
products of which then form the 
C3 convertase C4b2a, which 
cleaves to form C3a and C3b, the 
biologically active peptides. C3b 
consists of an alpha and beta 
chain. Cleavage of C3b by factor I 
produces an inactive form of C3b 
(iC3b) which remains bound to the target cell/structure. C3 then cleaves into a 
series of complement components in a sequential manner. These include C3a 
and C5a which act as chemoattractants to recruit microglia and other immune 
cells and promote inflammation (“find me”), and C3b and C5b which opsonize, 
or tag, the cell of interest for phagocytosis (“eat me”) (Stephan et al., 2012). 
The classical complement cascade has recently been implicated in 
responses unrelated to inflammation and immune response. Activation of the 
classical complement cascade during microglia-dependent developmental 
synaptic pruning (Tremblay et al., 2011) has led to the hypothesis that 
neurodegeneration is associated with an aberrant reactivation of complement-
mediated synaptic pruning as seen in development. Recently, the classical 
complement pathway has been implicated in neurodegenerative diseases such 
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as Alzheimer’s disease (Hong et al., 2016), multiple sclerosis (Michailidou et 
al., 2015) and in ischemia (Silverman et al., 2016). Immunohistochemistry and 
quantitative PCR analysis revealed an increase in a number of classical 
complement components in surgically removed human TLE tissue, including 
C1q and C3 , that occurred in the same area where neurodegeneration was 
observed. In a rat model of TLE, gene expression of complement proteins 
peaked at one week, corresponding with peak of microgliosis, and was also 
present at the chronic stages of epilepsy (Aronica et al., 2007).  Taken together 
these data suggest that complement peptides may be a candidate mechanism 
that guides microglia to eliminate dendrites and in an activity-dependent 
manner in the epileptic brain.   
Hypothesis 
Abnormal activation of the classical complement pathway after SE 
contributes to neuronal and dendritic loss in the CA1 area of the hippocampus, 
resulting in memory deficits and the development of chronic epilepsy. Inhibition 
of this pathway may rescue dendrites and neurons and will prevent 
hippocampal dependent malfunction. 
SE promotes activation and proliferation of microglia in the 
hippocampus. This microgliosis is associated with loss of neuronal and 
dendritic properties (Brewster et al., 2013; Schartz et al., 2016). High 
magnification microscopy and three dimensional reconstructions revealed that 
microglia make physical contacts with dendrites (Kettenmann, Kirchhoff, & 
Verkhratsky, 2013). After SE, the amount of contacts increases in the CA1 
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area of the hippocampus (Hasegawa, Yamaguchi, Nagao, Mishina, & Mori, 
2007), indicating a possible role of microglia in hippocampal-dendritic pruning 
and synaptic reorganization in epilepsy. Components of the classical 
complement pathway have been reported to guide microglia driven dendritic 
pruning in an activity dependent manner (Schafer et al., 2012). Specific 
peptides of this pathway such as C3a promote inflammation; and others such 
as C1q and C3b tag (opsonize) target cells for phagocytosis by microglia 
(Sarma & Ward, 2011). The findings that microgliosis occurs after SE and that 
complement proteins guide microglia-mediated phagocytosis led to the 
question of whether complement expression is altered in SE. In fact, mRNA 
expression for the classical complement cascade is increased in hippocampal 
tissue from human and experimental TLE (Aronica et al., 2007). For this 
reason, we explored the change in protein levels using western blot and 
spatiotemporal alterations after SE in these complement proteins using 
immunohistochemistry. To test the hypothesis that the classical complement 
cascade mediates microgliosis and the resulting injury to neurons and 
dendrites and the associated cognitive impairments, the pathway will be 
inhibited by the C1 esterase inhibitor (C1-Inh), which dissociates C1s and C1r 
from the C1 complex.  
Rationale 
Deficits in cognitive performance often occur in association with SRS in 
humans and in rodent models of SE and TLE (Chauviere et al., 2009; Holmes, 
2004; Jacobs et al., 2009; Nolan et al., 2003; Swann & Hablitz, 2000; Wong, 
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2005). These are often accompanied by hippocampal injury, specifically, 
dendritic injury, spine loss, and neuroinflammation (Brewster et al., 2013; 
Swann et al., 2000; Vezzani et al., 2011; Wong, 2005). Given that altered 
complement transcripts are seen in human TLE (Aronica et al., 2007), linked to 
seizure generation after acute viral infection (Libbey, Kirkman, Wilcox, White, & 
Fujinami, 2010), associated with cognitive disturbances in Alzheimer’s disease 
(Kolev, Ruseva, Harris, Morgan, & Donev, 2009), and C1q is increased after 
SE in hippocampus, we hypothesized that if SE-induced increased 
complement signaling promotes hippocampal-dependent learning and memory 
deficits then pharmacological complement inhibition will attenuate this 
pathophysiology. To test this hypothesis, we used a series of 
behavioral/cognitive tasks in groups of SE animals treated with vehicle or C1-
Inh (SE and SE+C1-Inh) compared to sham-treated controls. The extent of 
microgliosis, along with neuronal and dendritic alterations after SE and the 
effects of treatment with C1 esterase inhibitor were assessed using IHC and 
WB. We determined the efficacy of C1-Inh in the hippocampal neuronal and 
functional pathology using a series of histological, biochemical and behavioral 
tests (hippocampal-dependent memory function was evaluated using the novel  
object recognition task and the Barnes maze).  
 
 
Aim 1: To determine if SE evokes changes in the classical 
complement cascade and its association with dendritic 
changes in the hippocampus. 
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a. Identify the spatiotemporal profile of dendritic and microglia 
changes after SE. Immunohistochemistry (IHC) was used 
with antibodies against Map2 and IBA1. IR was quantified 
using densitometry analysis of different subregions of the 
hippocampi. Golgi staining was used to further determine 
alterations in dendritic spine density after SE. 
b. Identify how SE alters the levels and distribution of 
components of the classical complement pathway in the 
hippocampus. IHC was used to determine distribution and 
levels of C1q in hippocampal subregions at different time 
points after SE. Because C3b antibodies specific for 
histology were not commercially available, western blot 
(WB) analysis was used to measure protein levels of C3bα,  
C3bβ, and iC3b using a total C3 antibody specific for 
western blotting. 
c. Identify the cellular and sub-cellular localization of 
components of the classical complement pathway. 
Immunofluorescence (IF) was used to determine the 
colocalization of C1q with Map2.  
AIM 2: To test the hypothesis that abnormal classical 
complement pathway activation after SE contributes to 
dendritic loss as well as memory and learning deficits 
during the latent period. 
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a. Determine the role of the classical complement pathway in 
SE-induced pathology. Acute treatment with C1-Inh was 
administered subcutaneously at 4-, 24-, and 48-hours after 
an episode of SE. Tissue was collected at various time 
points after SE (3-35 days) and IHC was used to determine 
distribution and IR levels of Map2 and IBA1 in the 
hippocampus. 
b. Determine the role of the classical complement pathway in 
SE-induced cognitive deficits. NOR and BM were done at 2 
weeks after SE and C1-Inh treatment. Performance in 














 Male Sprague Dawley rats (150-250 grams) (Harlan Laboratories) were 
housed at the Purdue Psychological Sciences Building. Ambient temperature 
was constantly 22°C, with diurnal cycles of a 12-hour (hr) light and 12-hr dark 
(8:00 to 20:00 hr). All animals had access to unlimited food and water. 
Pilocarpine-Induced Status Epilepticus 
 Protocol for induction of SE modified from (Brewster et al., 2013). SE 
was induced in male Sprague Dawley rats using the chemoconvulsant 
pilocarpine. Thirty minutes before the intraperitoneal (i.p.) administration of 
pilocarpine hydrochloride (280-300mg/kg; Sigma Chemical Co., St Louis, MO, 
USA) rats were given scopolamine methyl bromide (1mg/kg, i.p; Sigma 
Chemical Co., St Louis, MO, USA) to minimize potential peripheral cholinergic 
effects of the pilocarpine. Control rats were given scopolamine and saline 
(sham). Behavioral observation was used to monitor seizure activity and 
recorded on the Racine scale (Racine, 1972). Rats were deemed to be in SE 
when they reached stage 5 (rearing and falling). After SE had continued for at 
least 45 minutes, rats were given an i.p. injection of Diazepam (10mg/kg; 
Hospira Inc., Lake Forest, IL, USA). Rats that were injected with pilocarpine but 
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did not develop SE were given Diazepam 1-2 hours after the injection of 
pilocarpine and included in a pilocarpine control group. Two to four hours after 
Diazepam administration, rats were given 1.5 mL of sterile 0.9% saline i.p. 
(AddiPak) and were checked daily to ensure proper weight gain and hydration. 
During the three days of recovery after SE, rats were fed apples, apple sauce, 
ensure, or fruit loops as needed. I.P. injections of saline were administered as 
needed as well.  
C1 Esterase Inhibitor Treatment 
 Rats were given Complement C1-esterase inhibitor, human (C1-inh) 
(EMD Medicals Inc., San Diego, CA, USA) after SE to inhibit the classical 
complement pathway. C1-Inh targets serine proteases C1r and S1s, thus 
preventing the formation of C3 convertase via the classical complement 
pathway. Control and SE rats were randomly selected to receive C1-inh 
injections or vehicle injections. Rats were given subcutaneous (s.c.) injections 
of C1-inh (20 U/kg) 4, 24, and 48 hours after the onset of SE.  
Open Field (OF)  
 As a measure of recovery time, an open field test was done 3 days after 
SE. Rats were placed in a square test chamber (62X62X46 cm) for twenty 
minutes under red light and recorded from above. Any-maze software was 
used to quantify measures of motility (e.g. distance travelled, velocity) and 




Novel Object Recognition (NOR) Test 
 The NOR test was used to assess hippocampal-dependent recognition 
memory in SE and SE+C1-Inh rats and sham-treated control rats. The protocol 
for NOR was modified from a previous study (Brewster et al., 2013). Rats were 
handled every day by experimenters for one week before behavioral testing 
began to allow the rats to acclimate to being handled. Behavioral testing began 
two weeks after the episode of SE. Before any behavioral testing, rats were 
acclimated to the central room of the suite for 30 minutes in single housed 
cages. Twenty-four hours prior to NOR, rats were habituated to the test 
chamber (62X62X46 cm) for 20 minutes. Habituation was recorded and used 
as an open field (OF) test for motility and anxiety. Any-maze software was 
used to score total distance traveled, average velocity, freezing, and percent 
time in the “inner zone.” The following day, rats were placed back in the testing 
chamber for five minutes and allowed to explore two identical objects, placed in 
opposite and symmetrical locations. After a two hour retention period, one of 
the objects was replaced with a novel object and the rats were allowed to 
explore for 5 minutes. The placement of the novel object was counterbalanced 
to control for side preference. Rats were placed facing the wall of the test 
chamber halfway between both objects to avoid any preference. Test chamber 
and objects were thoroughly cleaned with 70% ethanol between each trial. 
Exploration of the familiar and novel objects (defined by rats coming in contact 
with the objects, or < 1cm from the objects) was scored with Any-maze 
software, verified by hand scoring, and analyzed using paired t tests. 
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Barnes Maze (BM) 
 Twenty-four hours after NOR rats were tested for spatial memory using 
the BM test (Levin et al., 2012; Locklear & Kritzer, 2014). The maze consisted 
of a black circular platform (1.22 m diameter) elevated 1.68 meters with 18 
equally spaced holes (10.16 cm diameter) along the outer edges. The maze 
contained a removable escape box. Visual cues for navigation were placed on 
all walls (triangles, squares, etc.). Thirty minutes prior to BM all rats were single 
housed and acclimated in the adjacent room in the dark as bright light was 
used to create an anxiogenic condition during testing. Twenty-four hours before 
testing, rats were habituated to the table in red light conditions. All rats were 
first trained to find the hidden escape box in three steps, in which they were 
allowed to remain in the box undisturbed for 2 minutes, each separated by 15 
minutes: (1) rats were placed directly into the escape box; (2) rats were placed 
on the maze surface adjacent to the escape box and allowed to enter the box 
or gently guided into it; (3) the rats were placed on a temporarily constructed 
walkway leading from the center of the maze to the escape box. If the rats did 
not immediately walk towards the box they were gently guided into it. A single 
fruit loop was placed inside the escape box during habituation to provide a 
reward for entering the box. Training took place throughout the following 4 days 
with 4 trials per day separated by 15 min. The location of the escape box was 
rotated 180˚ from habituation. After acclimation, rats were placed in the center 
of the maze in an opaque start box. After a 10 second delay, bright lights were 
turned on and the start box was lifted. Rats were given up to 3 minutes to enter 
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the escape box or guided to it if they did not find it on their own. Once in the 
escape box rats were allowed to remain there for one minute. Latency to find 
the escape box was measured. The probe trial took place on the fifth day. All 
holes were covered and rats were given 90 seconds to explore the maze then 
returned to their home cages. Any-maze was used to determine the percent 
time spent directly on top of hole which previously contained the escape box 
(the target). Throughout testing, the maze was thoroughly cleaned with 70% 
ethanol and rotated to eliminate odor trails. The escape box was always in the 
same spatial location.  
Immunohistochemistry 
 Rats were deeply anesthetized with beuthenasia and perfused with ice 
cold 1X phosphate buffered saline (PBS; 137 mM NaCl, 2.7 mM KCl, 4.3 mM 
Na2HPO4, 1.47 mM KH2PO4, pH 7.4) followed by ice cold 4% 
paraformaldehyde (PFA). Brains were quickly dissected and post fixed in 4% 
PFA overnight. After cryoprotection in 30% sucrose, brains were frozen in pre-
chilled isopentane and stored at -80˚C until ready to use. Serial sections were 
taken at 30-50μm using a Leica CM1860 cryostat and stored in 1XPBS + 0.1% 
sodium azide. We used serial sections along the dorsoventral axis at 
approximately the following Bregma coordinates:  -3.00mm, -3.48 mm, -4.08 
mm, -4.36 mm, -4.92 mm, and -5.28 mm. These sections represent an equal 
sampling of the hippocampus along its dorsoventral axis. IHC was done in free 
floating sections. After a 5 minute (min) wash in 1XPBS, sections were 
incubated in hydrogen peroxide for 30 min followed by a 20 min wash in 
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1XPBS with 3% triton (T). Then brain sections were incubated in immunobuffer 
(5% goat serum, 0.3% BSA, 0.3% triton diluted in 1XPBS) for 1-24 hrs followed 
by a 24-48 hr incubation in primary antibody. Primary antibodies used include 
mouse anti-Map2, mouse anti-NeuN (1:3K; Millipore, Temecula, CA); rabbit 
anti-IBA1 (1:3K; Wako, Cambridge, MA); and rabbit anti-C1q (1:200; Abcam, 
Cambridge, MA). Following incubation in primary antibody, sections were 
washed with 1XPBS+0.1%T and incubated with goat anti-mouse or anti-rabbit 
secondary antibodies for a minimum of 1 hr at room temperature (RT). Then 
sections were incubated in avidin-biotin complex solution (ABC) diluted in 
1XPBS for 30 min before being put in 3,3’-Diaminobenzidine (DAB) peroxidase 
substrate solution following manufacturer instructions in order to produce a 
brown stain indicating immunoreactivity. Stained sections were mounted on 
gelatin covered slides, stained with cresyl violet, dehydrated in increasing 
concentrations of ethanol (50%-100%), de-fatted in xylene, and coverslipped 
using permount mounting medium. For colocalization studies with IF, 
biotinylated primary antibodies were used for Map2 and C1q and secondary 
antibodies conjugated with Alexa Fluor (405-647) were used. Sections were 
mounted on slides, air-dried, and coverslipped with Dako fluorescent mounting 
medium (Dako, Carpinteria, CA, USA). Immunoreactivity was visualized using 
a fluorescence microscope (Leica DM5500) followed by deconvolution 




Semi-Quantitative Densitometry Analysis 
 Imaging of immunostained brain sections was done with Leica DM500 
microscope and images were captured with high resolution digital camera 
(Leica MC120 HD) with 4X objectives using the LAS4.4 software. Relative 
mean pixel intensity was measured blinded to treatment group using Image J 
NIH software (V1.49). Densitometry analyses were performed bilaterally over 
the dorso-ventral axis of the hippocampus. Brain tissues that were damaged 
and the hippocampal anatomical landmarks were broken and thereby 
unrecognizable following the free-floating IHC procedures were excluded from 
the quantitative analyses. Therefore, between 4 and 6 sections were analyzed 
per brain.   
Western Blot 
 Rats were deeply anesthetized and perfused with ice cold 1XPBS. 
Hippocampi were rapidly dissected and stored in -80˚C until ready to use. 
Hippocampi were homogenized in ice-cold homogenization buffer (1XPBS 
containing 0.2% protease inhibitor cocktail). Bradford Protein Assay (Bio Rad, 
Hercules, CA, USA) was used to determine protein concentration. Samples 
were normalized and diluted in Laemmli loading buffer (4X: 0.25 M Tris, pH 
6.8, 6% SDS, 40% sucrose, 0.04% Bromophenol Blue, 200 mM Dithiothreitol). 
After SDS-PAGE proteins were transferred to polyvinylidene fluoride (PVDF) 
membranes. Membranes were incubated in blocking solution (5% non-fat milk 
diluted in 1X Tris Buffered Saline) with 0.1% tween (T) for one hour at room 
temperature. Then, membranes were incubated overnight at 4˚C in primary 
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antibody diluted in blocking solution. The primary antibodies used include goat 
anti-C3 (1:500; MP Biomedical (Cappel), Solon, OH) and rabbit anti-actin 
(1:5000; Sigma-Aldrich, St. Louis, MO). Following incubation with primary 
antibodies membranes were washed in 1X TBS-T (3x5 min). Membranes were 
then incubated for one hour at RT with secondary antibodies labeled with 
horseradish peroxidase: anti-rabbit IgG (1:5000; Vector Laboratories, 
Burlingame, CA) or anti-goat IgG (1:5000; ThermoFisher Scientific, Rockford, 
IL). Membranes were then washed in 1X TBS-T (3x5 min) and incubated with 
enhanced chemiluminescence (ECL) prime western blotting detection reagent 
(GE Healthcare, Buckinghamshire, UK). Immunoreactive bands were captured 
on autoradiography film. Films were developed and scanned for densitometry 
analysis. Some membranes were stripped from primary antibodies by 
incubating in stripping buffer (25 mM glycine, pH 2.0, 10% SDS) for 1-2 hours 
at RT. Membranes were then washed in 1X TBS-T (3x10 min), blocked, and 
re-incubated with different primary antibodies. 
Western Blot Analysis 
 Optical density of immunoreactive bands was measured using Image J 
NIH software (V1.49). Optical densities obtained for all bands of interest were 
normalized for loading to the actin levels within the same lane. All groups were 
normalized to the average of the control group.  
Golgi Staining 
 Rats were profoundly anesthetized with Beuthanasia and perfused with 
ice cold 1XPBS. All brains were rapidly dissected and processed using the FD 
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Rapid Golgi Stain kit following the manufacturer’s instructions (Neurodigitech, 
San Diego, CA, USA). Brains were incubated in Golgi impregnating solutions 
provided in the kit for 4 weeks. Brains were cut into serial coronal sections (80 
μm), mounted on gelatin-coated slides, and stained following the FD Rapid 
Golgi Stain kit protocol. After staining, sections were dehydrated through 
increasing alcohol concentrations [50%, 70%, 95%, 100%], de-fatted in Xylene, 
and coverslipped using Permount mounting media. Spine density was 
quantified using a 100X immersion (oil) objective with a Leica DM5500 
microscope equipped with a high definition Leica DFC290 camera and with the 
LASV4.6 software. Five representative sections were selected along the 
dorsoventral axis at approximately the following Bregma coordinates:  -3.48 
mm, -4.08 mm, -4.36 mm, -4.92 mm, and -5.28 mm. Five CA1 neurons were 
randomly selected per section. From these, the number of spines was counted 
in 20 μm sections of five second order dendrites per neuron as previously 
described (Brewster et al., 2013). Total dendritic branches analyzed per group: 
Control: 375; 3 day post-SE: 375; 14 days post-SE: 375; 35 days post-SE: 240. 
Brains per group: Controls: 3; 3 day post-SE: 3; 14 days post-SE: 3; 35 days 
post-SE: 2. 
Statistical Analysis 
 GraphPad Prism 6 software was used for statistical analyses and 
Analysis of Variance (ANOVA) with Tukey’s post hoc test to determine 
statistical significance (α < 0.05) between the control and experimental groups. 
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SE Triggers a Transient Decrease in Map2 Immunoreactivity in the CA1 
Hippocampal Area 
 We determined the temporal progression in the distribution of Map2 
immunostaining in the mature hippocampal formation at 4 hrs, 1-, 3-, 14-, and 
35- days after an episode of pilocarpine-induced SE (Fig. 1). Densitometry 
analysis followed by ANOVA revealed significant group effects for the intensity 
of Map2 IR signal in the CA1 pyramidal cell layer (pcl) and stratum radiatum 
(sr) [CA1 pcl, F(6, 39) = 6.40, p < 0.001; CA1 sr, F(6, 39) = 6.12, p < 0.001], as 
well as the molecular layer (ml) of the Dentate Gyrus (DG) [DG ml, F(6, 39) = 
3.35, p < 0.01] (Fig. 1I). In contrast, the intensity of Map2 IR localized in the 
CA3 region was not significantly altered by SE [4 hrs to 35 days (d)] when 
compared to the control group (CA3 pcl [F(6, 39) = 1.74, p = 0.13], CA3 sr [F(6, 
39) = 1.26, p = 0.30]). In control hippocampi, a homogenous distribution of 
Map2 IR was evident throughout the dendritic fields of CA1-3 sr (Fig.1A). High 
magnification images of the CA1 area showed a continuous Map2 staining 
pattern within the labeled dendritic structures of control hippocampi (Fig. 1A). 
At 4 hrs-1 d post-SE, the intensity of Map2 IR over the CA1 pcl and sr regions 
was comparable to that of the control group (p > 0.05) (Fig. 1B-C). Between 3  
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Figure 1. Temporal profile of Map2 immunostaining in the hippocampus after 
status epilepticus (SE). A, shows a representative image of the Map2 staining 
(brown) from a control hippocampus with a high magnification image of the 
CA1 area (boxed). B-H show representative hippocampal images with high 
magnification of boxed CA1 areas at different time points after an episode of 
SE (B, 4 hrs; C, 1 day (d); D, 3d; E-F, 14d; H, 35d). A representative image of 
a hippocampus from a rat that was given pilocarpine but failed to develop SE 
(pilo-non SE; Pilo in graphs) is shown in G. I, shows the densitometry analysis 
as relative mean pixel intensity for the different hippocampal sub-regions CA1 
pyramidal cell layer (pcl) and stratum radiatum (sr), CA3 pcl and sr, and the 
molecular layer (ml) of the dentate gyrus (DG). Note that significant differences 
in the intensity of Map2 immunoreactivity are evident within the CA1 region 
between the control group and 1-35d post-SE groups.  Data are shown as 
mean ± standard error of the mean. *, p < 0.05; **, p < 0.01; ***, p < 0.001 
compared to the control group. #, p < 0.05, comparison between 14d and 35d 
groups (n = 3-9/group) (shown inside the bar graphs).  ANOVA with Tukey’s 













and 14 days post-SE, the Map2 signal was gradually and significantly less 
intense than the control group in the CA1 sr (ctl vs 3d, p < 0.01; ctl vs 14d, p < 
0.001) region and significantly less intense in the CA1 pcl region at 14 days 
compared to control (p < 0.001) (Fig. 1D-F). 
Note that a number of dendrites displayed prominent punctated Map2 
staining by day 14. The significant decrease in Map2 IR in the CA1 area seen 
at two weeks post-SE was specific to the SE event. Rats that received the 
same dose of pilocarpine but did not develop class 5 seizures showed a 
hippocampal distribution of Map2 similar to controls (14 days pilo-non SE; Fig. 
1G) (p > 0.05). At 35 days following SE onset, the Map2 IR levels in CA1 pcl 
were significantly decreased compared to controls (p < 0.01) (Fig. 1H) and 
resembled that observed at 1-3 days post-SE (p > 0.05). However, a significant 
increase in the intensity of Map2 IR was observed between 14 and 35 days 
after SE (p < 0.01) suggesting a partial recovery of Map2 IR in the CA1 region.   
To determine whether dendritic arborizations were present in the CA1 
region at the time points when Map2 was significantly decreased, we 
performed Golgi staining in controls and at 3-, 14- and 35-days post-SE (Fig. 
2). While Golgi impregnation was evident throughout all hippocampal regions, 
the structural analysis of dendritic arborizations was largely obstructed by the 
presence of Golgi impregnated glial cells in all SE groups. Thus, we quantified 
the spine density of second order CA1 dendritic branches and performed an 
ANOVA to determine a group effect [F(3, 1361) = 10.01, p < 0.001]. We found 
that in parallel to Map2 decline, spine density was significantly decreased at  
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Figure 2. Temporal profile of changes in spine density in hippocampal CA1 
cells after status epilepticus (SE). A-D, shows representative images of golgi 
impregnated hippocampal dendrites from a control rat (A) and at different time 
points following an episode of SE (B, 3 days (d); C, 14d; D, 35d). E, shows 
representative images of 20 µm sections of CA1 dendritic branches from a 
control, and 3-, 14- and 35- days post-SE. F, shows the quantitative analysis of 
spine density in all groups. Data are shown as mean ± standard error of the 
mean. *, p < 0.05; ***, p < 0.001 compared to the control group. N numbers of 
dendritic branches quantified per animal are shown inside the bar graphs.  









3-, 14- and 35-days post-SE when compared to the control group (ctl vs 3d, p < 
0.001; ctl vs 14d, p < 0.001; ctl vs 35d, p < 0.05).  
SE Triggers a Transient Increase in Microgliosis That is Prominent in the 
CA1 Region 
 We previously showed that Map2 loss in the CA1 area correlated with 
accumulation of hypertrophied microglia at 2 and 3 weeks after SE (Brewster et 
al., 2013). However, little is known about the temporal progression between 
these events in the same tissues. Therefore, in parallel to Map2 and in 
consecutive brain sections, we mapped the temporal profile of SE-induced 
microglial changes in the hippocampus using IBA1 to identify these cells (Fig. 
3). Densitometry analysis of IBA1 signal followed by ANOVA showed a 
significant group effect in areas CA1, CA3 and hilus [CA1, F(6, 43) = 14.71, p < 
0.001; CA3, F(6, 42) = 5.81, p < 0.001; hilus, F(6, 42) = 6.22, p < 0.001] (Fig. 
3I). In the control group, immunostaining showed a homogeneous distribution 
of IBA1-positive microglial cells throughout the hippocampal regions CA1, CA3, 
and DG (Fig. 3A). Higher magnification images from the CA1, CA3, and DG 
areas showed that in control hippocampi the morphological features of 
microglial cells included small cell bodies with highly branched and elongated 
processes (Fig. 3A, arrows). We found that SE triggered changes in the 
morphology and accumulation of IBA1-stained microglial cells in the 
hippocampus that progressed between 4 hrs and 35 days (Fig.3B-H).  Four hrs 
after SE onset, the processes of microglial cells localized throughout all 
hippocampal regions (CA1, CA3 and DG) were hypertrophied compared to  
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Figure 3. Temporal profile of IBA1 immunostaining in the hippocampus after 
status epilepticus (SE). A-H, show representative images of the IBA1 staining 
(brown) from a control hippocampus (A) and from hippocampi collected at 
different time points after an episode of SE (B, 4 hrs; C, 1 day (d); D, 3d; E-F, 
14d; H, 35d). A representative hippocampus from a rat that was given 
pilocarpine but failed to develop SE (pilo-non SE; Pilo in graphs) is shown in G. 
Right panels show high magnification images of boxed CA1, CA3, and the hilus 
of the dentate gyrus (DG). High magnification images with IBA1-labeled 
microglia (arrows) are also shown. Nissl stained cellular nuclei are shown in 
blue. Abbreviations: pcl, pyramidal cell layer; sr, stratum radiatum; slm, stratum 
lacunosum-moleculare. I, shows the densitometry analysis as relative mean 
pixel intensity for the different hippocampal sub-regions CA1, CA3, and hilus. 
Significant differences in the intensity of IBA1-stained microglia are evident in 
the CA1, CA3, and hilar regions at 4 hrs and 14d after SE compared to the 
control group. Data are shown as mean ± standard error of the mean. *, p < 
0.05; **, p < 0.01; ***, p < 0.001 compared to the control group. #, p < 0.05, 
comparison between 14d and 35d groups (n = 4-11/group) (shown inside the 






those of control hippocampi. Furthermore, the levels of IBA1 IR at 4 hrs after 
SE were significantly increased throughout all hippocampal regions compared 
to the control group (CA1, p < 0.05; CA3, p < 0.05; hilus, p < 0.05). By day 1 
after SE, the morphology of microglial cells and IBA1 IR levels were similar to 
the control group (p > 0.05) (Fig. 3C). At 3 days post-SE, drastic changes were 
evident in the morphology of microglial cells from highly branched to amoeboid 
(Fig. 3D). Throughout the hippocampus, smaller amoeboid microglia displayed 
shortened processes at 3 days after SE compared to the earlier time points 
and to the control group (Fig. 3A-D). By two weeks post-SE, a robust 
immunostaining for IBA1-positive amoeboid microglia was concentrated within 
the pcl, sr, and slm of the CA1 region (Fig. 3E-F). At this time point the 
presence of amoeboid microglia also was evident in the CA3 pcl and in the 
hilar region of DG, albeit at a lesser extent to that observed in the entire CA1 
area. Statistical analyses showed a significant increase in the intensity of IBA1 
IR at 14 days post-SE compared to the control group in all hippocampal 
regions (CA1, p < 0.001; CA3, p < 0.01; DG, p < 0.01). The intensity of IBA1 
signal in the 14 day pilo-non SE group was not different from controls in all 
hippocampal areas (p > 0.05) (Fig. 3G). Furthermore, we found that the drastic 
SE-induced changes on microglial morphology and accumulation in the CA1 
hippocampus were nearly resolved by 35 days after SE (Fig. 3H). Note that at 
this time point IBA1 IR was significantly less intense when compared to the 14 
day post SE-time point in all hippocampal regions (CA1, p < 0.01; CA3, p < 
0.01; DG, p < 0.01) and not significantly different to controls (p > 0.05).  
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SE Triggers a Transient Increase in the Classical Complement 
Component C1q in the CA1 Stratum Radiatum Hippocampal Subregion 
Previous studies demonstrated that proteins of the classical complement 
pathway, which is initiated by C1q, can tag neuronal elements for microglia to 
recognize and eliminate (Schafer et al., 2012). For instance, C1q and its 
downstream effector C3b are associated with the activity-dependent 
elimination of synapses in the normal developing brain (Stephan et al., 2012; 
Stevens et al., 2007). Enhanced attraction and contacts between microglial 
processes and CA1 dendrites occur following SE (Brewster et al., 2013; Eyo et 
al., 2014; Hasegawa et al., 2007). However, the functional significance of these 
contacts is not known. Thus, we investigated whether C1q and C3 proteins 
from the classical complement pathway were altered after SE. First, we 
determined the distribution of C1q in the CA1 region of the hippocampus (Fig. 
4), where substantial loss of Map2 and accumulation of IBA1-positive microglia 
were observed (Figs. 1, 3) (Brewster et al., 2013; Schartz et al., 2016). We 
focused on the time points in which significant changes in Map2 and IBA1 were 
observed (3-35 d) and performed IHC with antibodies against C1q. In the 
control group, immunostaining showed a distribution of C1q (Fig. 4A) that was 
mainly localized to the slm of the CA1 region. In contrast, after SE the IR signal 
for C1q appeared throughout the CA1 pcl, sr and slm regions (Fig. 4B-4E). 
Densitometry analysis of C1q IR followed by ANOVA showed no overall group 
differences between control hippocampi and hippocampi taken at 3-, 14-, 25-, 
or 35-days after SE in the pcl [F(5, 31) = 1.76, p = 0.16] or the sr [F(5, 31) =  
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Figure 4. Temporal profile of C1q immunostaining in the hippocampus after 
status epilepticus (SE). A-E, show representative images of the C1q staining 
(brown) from a control hippocampus (A) and from hippocampi collected at 
different time points after an episode of SE (B, 3 days (d); C, 14d; D, 23d; E, 
35d). Nissl stained cellular nuclei are shown in blue. F, shows the densitometry 
analysis as relative mean pixel intensity for hippocampal subregions CA1 
pyramidal cell layer (pcl) and stratum radiatum (sr). Significant differences in 
the intensity of C1q immunoreactivity are evident in the CA1 sr subregion at 
14d after SE compared to the control group. G, shows colocalization of C1q 
(green) with Map2 (red), in control CA1 hippocampi and in hippocampi from 3-, 
and 14-days after SE. Note that due to the low intensity of Map2 IR at 14 days, 
potential colocalization with C1q is inconclusive. Data are shown as mean +/- 
standard error of the mean. N numbers of animals used are shown inside the 











2.15, p = 0.08]  of the CA1 hippocampus (Fig. 4F). However, since the most 
drastic changes in microglia and Map2 IR are observed at 14 days after SE, we 
directly compared C1q IR in control hippocampi and hippocampi from 14 days 
post-SE. An unpaired T test revealed a significant increase in C1q IR in the sr 
of the CA1 region 14 days after SE when compared to the control [t(14) = 2.25, 
p < 0.05]. 
SE Triggers a Transient Increase in C3 and Its Cleavage Products in the 
Hippocampus 
Complement protein C3 is activated downstream of C1q. Upon 
activation, C3 is cleaved into its biologically active products C3a and C3b. C3a 
is released and works to attract microglia to the site of interest and C3b works 
to opsonize cells, cellular structures, or debris for microglia to engulf and 
eliminate (Stephan et al., 2012). We used western blotting to quantify the 
cleavage of C3 in whole hippocampal homogenates from different time points 
after SE (14, 21 and 35 days) and compared them to age matched controls 
(Fig. 5). Note that commercially available antibodies for C3b with rat specificity 
were not available for our histological studies; therefore we used an antibody 
against all C3 forms for western blotting. Figure 5A shows a representative 
western blot including several time points (14-35 d) next to age matched 
control samples. The immunoblot shows an overall increase in C3 protein 
levels in all the SE groups as compared with the respective controls. We 
analyzed the western blots with a series of unpaired t tests of the SE and 
control matched time points for three different immunoreactive bands  
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Figure 5. Temporal profile of C3 protein levels and cleavage after an episode of 
status epilepticus (SE). A, shows representative western blot of C3 in 
hippocampi dissected at different time-points (14-, and 25-, and 35-days) after 
SE loaded next to respective age-matched controls. Different bands represent 
cleavage products of C3: C3bα, C3bβ, and iC3b. Below is the same blot 
immunoblotted with actin, the loading control. B, shows the densitometry 
analysis as percent pixel intensity for C3bα, C3bβ (C), and iC3b (D). All 
experimental time points were compared to their corresponding controls. Data 
are shown as mean +/- standard error of the mean.  N numbers of animals 
used are shown inside bar graphs.  *, p < 0.05, #, p = 0.06. Unpaired t test. 













representing C3bα, C3bβ, and iC3b. Densitometry analysis revealed a 
significant increase in the protein levels of C3bβ at 14 days after SE when 
compared to controls [t(10) = 2.56, p < 0.05]. Furthermore, there was a trend 
for an increase in levels of iC3b at 35 days post SE when compared to their 
age matched controls [t(5) = 2.39, p = 0.06]. Increasing the sample size at later 
time points may provide more definitive information about levels of C3 after SE. 
 Because complement activation after SE occurs at the same time points 
as the drop in Map2 and the peak of microgliosis, we hypothesized that the 
classical complement pathway may be driving the microglia-mediated dendritic 
alterations. In addition, because it is likely that these alterations in the 
hippocampus are driving cognitive deficits observed in models of SE (Brewster 
et al., 2013; Pearson et al., 2014), inhibiting this pathway may attenuate 
dendritic alterations and associated behavioral deficits. We therefore used C1-
Inh to block activation of the classical complement pathway immediately after 
SE and evaluated the time-course of microgliosis and dendritic alterations, 
along with cognitive function as measured with tests such as NOR and BM 
(Fig. 6). 
Acute Treatment With C1-Inh Does not Attenuate Map2 Loss in the CA1 
Region of the Hippocampus 
Since aberrant activation of the classical complement pathway coincides 
with dendritic alterations after SE, we used a pharmacological approach to 
inhibit complement activation via the classical pathway immediately following 











Figure 6. Experimental paradigm for treatment with C1-esterase inhibitor (C1-
Inh) after status epilepticus (SE). The timeline of SE induction (day 0), C1-Inh 
treatment (20U/kg, s.c; days 0, 1, and 2), tissue collection (days 3, 14, 25, and 
35), and behavioral testing [open field (OF), novel object recognition (NOR), 





C1-inh was administered subcutaneously at 4-, 24-, and 48-hrs after SE and 
tissue was collected at 3-, 14-, and 25-days after SE and processed for IHC 
with antibodies against Map2 (Fig.7). Map2 IR within the CA1 hippocampal 
region was quantified using densitometry analysis and compared to the control 
and experimental tissue from the time course analysis of Map2 (Fig. 1). Figure 
7A shows a representative control section stained for Map2. There is 
homogenous distribution of Map2 throughout the dorso-ventral axis of the 
hippocampus. Figures 7B-D show the time course of Map2 distribution in SE 
and SE+C1-Inh with representative dorsal and ventral sections at 3-, 14-, and 
25-days after SE. Densitometry analysis revealed a reduction in Map2 IR at all 
time points after SE (Fig. 7E) when compared to the control group [F(3, 35) = 
16.76, p < 0.001]. Map2 IR levels in the SE+C1-Inh groups were significantly 
reduced when compared to the control group [F(3, 27) = 12.36, p < 0.001].  
Interestingly, we found that C1-Inh administered to SE rats did not attenuate 
the SE-induced reduction of Map2 IR in the hippocampal CA1 region.  
Significant differences were not evident at 3, 14 or 25 days in the SE+C1-inh 
group compared to the respective SE groups.  
Acute Treatment With C1-Inh Exacerbates Accumulation of Microglia to 
the CA1 Region of the Hippocampus 
We next sought to determine if treatment with C1-Inh after an episode of 
SE could prevent the aberrant accumulation and activation of microglia. 
Activation of the classical pathway C1q-C3 produced biologically active 
peptides that serve various functions including recruitment of microglia and  
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Figure 7. C1-esterase inhibitor (C1-Inh) treatment does not attenuate Map2 
loss in CA1 hippocampus after an episode of status epilepticus (SE). A, shows 
a representative image of the Map2 staining (brown) from a control brain. B-D, 
show representative brain images at different time points after an episode of 
SE, next to an image from matching time-points after SE with C1-Inh treatment 
(B, 3 days (d); C, 14d; D, 25d). E, shows the densitometry analysis of Map2 
immunoreactivity (IR) as percent control pixel intensity for the hippocampal 
CA1 region. Note that Map2 IR is lowest at 14d after SE, and is not altered with 
C1-Inh treatment compared to SE. Data are shown as mean ± standard error of 
the mean. N numbers of animals used are shown inside bar graphs.  **, p < 
0.01; ***, p < 0.001 compared to the control group (n  =  4–20/group). ANOVA 








macrophages and promote inflammation, in addition to the eat me signals C1q 
and C3b (Stephan et al., 2012).  
 Tissue collected at 3-, 14-, and 25-days after SE with C1-Inh treatment 
was immunostained with antibodies against IBA1 (brown), a marker for 
microglia, and IR signal was quantified with densitometry analysis (Fig. 8). We 
compared the SE+C1-Inh group with the time-matched SE and control 
samples. Densitometry analysis was restricted to the CA1 region of the 
hippocampus where substantial microgliosis was previously observed after SE 
(Fig. 3) (Brewster et al., 2013; Schartz et al., 2016). Figure 8A shows a 
representative control section stained for IBA1. There is light homogenous 
distribution of IBA1 throughout the dorso-ventral axis of the control 
hippocampus. Figures 8B-D show the time course of IBA1 distribution in SE 
and SE+C1-Inh with representative dorsal and ventral sections at 3-, 14-, and 
25-days after SE. ANOVA revealed a significant group effect on the levels of 
IBA1 IR across the groups [F(6, 51) = 20.34, p < 0.001]. Specifically, post hoc 
analysis showed that there was a significant increase in IBA1 IR levels in the 
CA1 hippocampus at 3 days in the SE+ C1-Inh group when compared to 
control samples (p < 0.01) whereas no difference was observed between the 
control group and SE group at 3 days after SE (Fig. 3). Additionally, the IR 
levels of IBA1 were significantly higher at in the SE+C1-Inh groups (14 and 25 
days)  in comparison to the control samples  (Fig. 8E) (ctl vs 14d SE+C1-Inh, p 
< 0.001; ctl vs 25d SE+C1-Inh, p < 0.001). Interestingly, IBA1 IR levels were 
also significantly higher in the SE+C1-inh groups when compared to the SE  
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Figure 8. C1-esterase inhibitor (C1-Inh) exacerbates microgliosis in the CA1 
hippocampus after status epilepticus (SE). A, shows a representative image of 
the IBA1 staining (brown) from a control brain. B-D, show representative brain 
images at different time points after an episode of SE, next to an image of a 
matching time-point after SE with C1-Inh treatment (B, 3 days (d); C, 14d; D, 
25d). E, shows the densitometry analysis of IBA1 immunoreactivity (IR) as 
percent control pixel intensity for the hippocampal CA1 region.  Note that 
significant differences in the intensity of IBA1 IR are evident at 3 days after SE 
with C1-Inh treatment and persist up to 25 days, whereas without C1-Inh 
treatment IBA1 immunoreactivity peaks at 14 days and decreases thereafter. 
Data are shown as mean ± standard error of the mean. N numbers of animals 
used are shown inside bar graphs.  *, p < 0.05; ***, p < 0.001. ##, p < 0.01; 
###, p < 0.001 compared to the control group (n  =  4–20/group). ANOVA with 








group [F(5, 32) = 8.41, p < 0.001]. Taken together these data suggest that 
acute treatment with C1-Inh may exacerbate SE-induced microgliosis in the 
hippocampus.  
Cognitive deficits are often comorbid in humans with TLE; these 
observations are replicated in experimental models of SE and acquired TLE 
(Brewster et al., 2013; Chauviere et al., 2009; Jacobs et al., 2009; Lesting, 
Geiger, Narayanan, Pape, & Seidenbecher, 2011; Levin et al., 2012; Muller, 
Bankstahl, Groticke, & Loscher, 2009; Nolan et al., 2003; Pearson et al., 2014; 
Swann & Hablitz, 2000; Szyndler et al., 2005; Wong, 2005). Interestingly, 
cognitive and behavioral impairments observed in epilepsy are often common 
with those seen in Alzheimer’s disease (Chin & Scharfman, 2013). This is 
important because aberrant levels of complement transcripts are found in 
human TLE (Aronica et al., 2007) and also in Alzheimer’s disease (reviewed in 
(Kolev et al., 2009)) and thus suggest a role for aberrant complement system 
activation in the mechanisms underlying cognitive disturbances. Building upon 
these studies and our findings that increased protein levels of C1q and 
cleavage of C3 occur after SE (Figs. 4, 5) we hypothesized that a SE-induced 
aberrant activation of the complement system may increase the risk of 
hippocampal-dependent memory deficits and that inhibition of the classical 




Motility and Anxiety-Like Behaviors are not Altered Following SE or C1-
Inh Treatment 
As a control for future behavioral studies, we evaluated the in the 
locomotion of all rats (controls, SE and SE+C1-Inh rats) using the open field 
test. Experiments were done at 14 days following SE. Rats were placed in an 
open square testing arena in the dark for 20 minutes and the following 
measures were analyzed: total distance travelled, average velocity, percent of 
time spent in the inner portion of the arena, and percent time freezing (Fig. 9).  
An analysis of measures of motility revealed no overall group effect on 
distance travelled [F(2, 46) = 1.79, p = 0.18] or velocity [F(2, 46) = 1.79, p = 
0.18] (Fig. 9A-B). Interestingly, an unpaired t test revealed that the SE group 
covered more distance than the control group [t(35) = 2.15, p < 0.05]. This 
finding is indicative of hyperactivity associated with epilepsy and potentially 
ADHD (Ramos, Carreiro, Scorza, & Cysneiros, 2016). However, because our 
ANOVA was not significant, more precise measures are needed to further 
explore this effect. We also analyzed measures of anxiety-like behavior with 
ANOVA and found no group effect of time spent in the inner portion of the open 
field arena [F(2, 46) = 1.77, p = 0.18] or percent of time freezing [F(2, 46) = 
1.46, p = 0.24]. The time spent in the inner portion of the arena can be 
associated with decreased anxiety, because the rats would spend more time 
along the tall walls of the arena if anxiety levels were increased. More time 
freezing would be indicative of increased anxiety, as rats have an instinctual 







Figure 9. Status epilepticus (SE) does not alter behavior in the open field test. 
Open field test was done at 14 days after SE on control rats, and those 
exposed to SE with and without the C1 esterase inhibitor treatment (C1-Inh). 
The distance traveled (a) and velocity (b), were not different between the 
groups. Similarly, measures of anxiety such as time spent in the center of the 
testing arena (c) or amount of freezing (d) were not changed. No significant 
differences were found (n = 12-19/group). N numbers of animals used are 
shown the inside bar graphs. Data are shown as mean +/- standard error of the 




Note that this test was also performed at 3 days post SE (Fig. 10). No 
differences between groups were observed [distance, F(2, 15) = 0.37, p = 0.69; 
velocity F( 2, 15) = 0.36, p = 0.70; inner duration, F(2, 15) = 1.23, p = 0.32; 
freezing, F(2, 15) = 0.20, p = 0.82]. Taken together these data suggest that at 3 
days after SE there are no deficits in locomotion across the groups while at 14 
days a trend for deficits starts to become evident. Future studies will determine 
whether locomotion and anxiety are altered at later time points, as 
epileptogenesis progresses in this model of acquired TLE. 
Recognition Memory Deficits are not Attenuated With C1-Inh Treatment 
Following SE 
To identify potential SE-induced changes in hippocampal-dependent 
memory function we used the NOR test. Specifically, the NOR test was used to 
measure changes in recognition memory after SE and SE with C1-inh 
treatment relative to age-matched controls (Fig. 11). Testing was done at 2 
weeks after SE because previous studies have confirmed that a deficit occurs 
at this time after SE (Brewster et al., 2013) and paralleled the histopathological 
changes (Figs. 1-3). During the first trial, rats were given 5 minutes to explore 
two identical objects under red light. The percent time spent with each object 
was measured (Fig. 11A). A paired t test showed no preference for either the 
left or right object in any group [control, t(20) = 0.21, p = 0.83; SE t(20) = 0.44, 
p = 0.66; SE+C1-inh, t(10) = 0.31, p = 0.76]. After a two hour delay, rats were 
placed back in the testing arena with one previously explored ‘familiar’ object 






Figure 10. Open field test 3 days after an episode of SE. Three days after SE, 
rats were tested in an open field paradigm to detect differences in recovery 
between control, SE, and SE+C1-Inh groups. The distance traveled (a) and 
velocity (b), were not different between the groups. Similarly, measures of 
anxiety such as time spent in the center of the testing arena (c) or amount of 
freezing (d) were not changed. No significant differences were found (n = 12-
19/group). N numbers of animals used are shown the inside bar graphs. Data 







Figure 11. Treatment with C1-esterase inhibitor (C1-Inh) does not attenuate 
recognition memory in rats subjected to status epilepticus (SE). The novel 
object recognition (NOR) test was used to measure recognition memory after 
SE and after SE with C1-Inh treatment. A, shows the percent exploration time 
of each object during the first trial. None of the treatment groups showed 
preference for either the right or the left object. B, shows the percent 
exploration time during the second trial. Note that only the control animals 
showed any preference towards the novel object, thus recognition of the 
familiar object. Data are shown as mean +/- standard error of the mean. *, p < 
0.05 (n = 11-21/group). N numbers of animals used are shown inside bar 
graphs.  ANOVA with Tukey’s post hoc test. 
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rats spent more time exploring the novel object [t(20) = 2.77, p = 0.01] 
suggesting they remembered the familiar object from the previous trial. 
However, both the SE and SE+C1-inh rats spent an equal amount of time 
exploring the novel and familiar objects. Lack of exploratory preference toward 
the novel object suggests failure to recognize the familiar object in the SE and 
SE+C1-Inh groups [SE, t(20) = 1.53, p = 0.14; SE+C1-inh, t(11) = 0.02, p = 
0.98] and thereby suggesting a memory deficit. Of importance, an ANOVA 
showed no differences in total exploration time between the control group and 
the experimental groups in either NOR trial 1[F(2, 50) = 0.38, p = 0.68] or NOR 
trial 2 [F(2, 50) = 0.20, p = 0.82. 
Hippocampal-Dependent Spatial Memory Deficits Induced by SE are not 
Attenuated With C1-Inh  
The Barnes maze (BM) test was used to assess changes in 
hippocampal-dependent spatial memory after SE and SE with C1-inh treatment 
relative to age-matched controls. ANOVA was used to compare performance 
(measured by latency to find the escape box) over 4 days of training between 
groups (Fig. 12A). There was a significant effect of treatment [F(2, 120) = 
40.89, p < 0.001], revealing a deficit in experimental rats throughout BM 
training. On the first training day, no significant differences were observed in 
mean latencies for finding the escape box (ctl = 74.62 ± 12.07s; SE = 94.98 ± 
8.39s; SE+C1-Inh = 113.40 ± 15.43s). On the second training day, SE+C1-Inh 
rats (M = 115.70 ± 18.21s) performed worse than control rats (M = 34.46 ± 
12.45s,) p < 0.001) and worse than SE rats (M = 60.33 ± 7.72s,p < 0.01),  
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Figure 12. Treatment with C1-esterase inhibitor (C1-Inh) does not attenuate 
spatial memory in rats subjected to status epilepticus (SE). Barnes Maze (BM) 
was used to assess spatial memory after SE and after SE with C1-Inh 
treatment. A, the rats were trained over 4 days (4 trials per day) to find an 
escape hole on a circular table with “false holes.” The graph shows the latency 
to find and enter the escape box during the training period.  Data are shown as 
mean +/- standard error of the mean.  *, p < 0.05; **, p < 0.01; ***, p < 0.001 
compared with control. B, Probe trial measuring time spent over the covered 
escape box (s). Data are shown as mean +/- standard error of the mean. *, p < 
0.05 compared to control group. C, shows representative tracking of the rats’ 












taking longer than both groups to find the escape box.) On day three, both SE 
and SE+C1-Inh groups showed a deficit in finding the escape box as compared 
to control [ctl vs. SE, p < 0.05; ctl vs SE+C1-inh, p < 0.001]. On average it took 
73.25 ± 14.00 seconds and 132.2 ± 20.57 seconds for the SE and SE+C1-Inh 
groups to find the escape box, compared to 33.96 ± 11.00 seconds from the 
control group. Surprisingly, the deficit of the SE+C1-Inh group was greater than 
the SE group (p < 0.01) at this point. On the fourth and last day of training, the 
deficit was still present in the SE (M = 89.04 ± 8.45s) and SE+C1-inh (M = 
132.30 ± 17.13s) groups when compared to controls (M = 29.50 ± 7.66s) 
(control vs. SE, p < 0.01; control vs SE+C1-Inh, p < 0.001). These data support 
the presence of a significant and persistent spatial learning deficit in rats that 
have had an episode of SE even with C1-inh treatment.  
Twenty-four hours after the last training session, rats were placed back 
on the BM table for a probe trial in which the escape hole was covered. Rats 
were allowed to explore the maze for 90 seconds and the amount of time spent 
directly on top of the hole that previously contained the escape box (the target) 
was measured and compared between groups (Fig. 12B). An ANOVA revealed 
a group effect in amount of time spent on top of the target [F(2, 30) = 4.83, p < 
0.05]. Specifically, post hoc tests showed that the control group spent 
significantly more time on top of the target than the SE (p < 0.05) or SE+C1-Inh 
(p < 0.05) groups suggesting a deficit in memory retention in both experimental 
groups. Figure 12C shows representative tracking during the probe trial for 
control, SE, and SE+C1-Inh rats. Although all three groups spent more time in 
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the quadrant that contained the target, the control groups spent more time 
directly on top of the target than the SE and SE+C1-Inh groups. These results 
indicate that SE results in a deficit in both spatial learning and spatial memory, 












The first aim of this study describes the spatial and temporal correlation 
between the SE-induced changes in Map2 IR, microglial accumulation, and 
activation of the complement pathway in the hippocampal formation at various 
time points following an episode of SE. Specifically, we found that, (1) SE 
triggered a decline in Map2 IR in the CA1 hippocampal pcl and sr areas that 
was evident as early as 1 day after SE, reached minimal expression at 14 
days, and was partially increased by day 35 post-SE (Fig. 1); (2) SE induced 
changes in the morphology of microglial cells that were evident as early as 4 
hrs post-SE in all hippocampal regions; however, at 2 weeks post-SE maximal 
accumulation of hypertrophied/amoeboid microglia was evident mainly within 
the CA1 area from where it declined thereafter (Fig. 3); and (3) Proteins of the 
classical complement cascade increase in the hippocampus at 14 days after 
SE (Figs. 4, 5) which corresponds to the peak loss of Map2 and accumulation 
of microglia. Even though alterations in Map2 and microglia within the 
hippocampal formation are often seen subsequent to SE and in epilepsy 
(Avignone et al., 2008; Ballough et al., 1995; Brewster et al., 2013; Choi & Koh, 
2008; De Simoni et al., 2000; Jalava et al., 2007; Ravizza et al., 2005; Rizzi et 
al., 2003; Shapiro et al., 2008; Vezzani & Granata, 2005), and complement 
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mRNA have been shown to be altered after SE (Aronica et al., 2007),  this 
study is the first to describe that the evolution of these events follow similar 
spatial and temporal profiles in a model of SE and acquired temporal lobe 
epilepsy. Furthermore, this study is the first to describe temporal changes of 
the classical complement pathway after an episode of SE in parallel to dendritic 
structural alterations and microgliosis. 
Spatiotemporal analyses of SE-induced Map2 changes in the 
hippocampus have been previously reported in the developing brain (Jalava et 
al., 2007). SE in the immature brain triggers transient increase in the high 
molecular weight Map2 protein, which is the dominant Map2 isoform in the 
adult brain (Jalava et al., 2007; Sanchez, Diaz-Nido, & Avila, 2000). In contrast, 
we found that SE in the mature brain triggers a decline in Map2 IR that is more 
prominent in the CA1 hippocampal region (Fig. 1). First, we observed that the 
extent to which Map2 IR was decreased in CA1 pcl and sr was similar 
suggesting a global reduction of Map2 protein in CA1 cells. This could be due 
to alterations in the activation of intracellular signaling cascades such as  
mTOR and/or MAPK/ERK pathways which have been shown to regulate 
protein synthesis of Map2 and also are altered by SE (Brewster et al., 2013; 
Gong & Tang, 2006; Lugo et al., 2008).  
Map2 loss in the hippocampal CA1 region may impact the morphology 
and stability of the dendritic structures. This is supported by studies showing 
that Map2 deficient mice display reduced dendritic lengths along with 
decreased microtubule densities (Harada et al., 2002). Map2-microtubule 
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stability is important for neuronal homeostasis which includes cellular 
processes such as protein trafficking (Dehmelt & Halpain, 2005; Gardiner, 
Overall, & Marc, 2011; Harada et al., 2002; Urbanska, Blazejczyk, & Jaworski, 
2008). The finding that the maximal reduction in Map2 IR at two weeks after 
SE was no longer evident at 35 days post-SE suggests a partial recovery of 
Map2 IR in CA1 and thereby a transient SE-induced effect.  
Furthermore, a number of studies support that when neurons are 
challenged with abnormal activity (i.e. seizures) their physiological responses 
adapt to the initial imposed changes most likely trying to restore normal activity 
patterns (homeostatic plasticity) (Swann & Rho, 2014). Thus, it is possible that 
the SE-induced transient decline of Map2 IR may be an attempt of potentially 
viable CA1 cells to maintain stability of their dendritic structures along with 
neuronal functions and thereby may be a beneficial event. However, because 
Map2 is critical for the stability and growth of dendritic elements (Dehmelt & 
Halpain, 2005; Gardiner et al., 2011; Harada et al., 2002; Urbanska et al., 
2008) it is also possible that the temporary reduction of this protein directly 
contributes to the decline in dendritic arborization and spine densities of 
hippocampal CA1 cell (Wong, 2005; Wong & Guo, 2013). At the time points 
when Map2 IR levels were the most significantly reduced (3-35 days post-SE), 
we quantified the dendritic spine densities of CA1 cells and found a significant 
decline (Fig. 2) suggesting a correlation between these events. Nevertheless, 
the possibility that homeostatic mechanisms involving transcriptional, 
translational, or cellular transport/trafficking processes underlie changes in 
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Map2 levels, and whether SE-induced Map2 loss is detrimental or beneficial for 
viable neurons requires investigation. Taken together these data suggest that 
there is a spatial and temporal association between reduced Map2 levels and a 
decrease in spine density following pilocarpine-induced SE in the mature rat 
hippocampus. 
It is also expected that some of the SE-induced Map2 loss is directly a 
consequence of neuronal death and injury (Ballough et al., 1995). We 
previously mapped the progression of cleaved caspase-3 after an episode of 
SE and found a peak in IR at 3 days post-SE (Schartz et al., 2016). The 
unparalleled temporal progression of maximum apoptosis with that seen for 
Map2 at two weeks suggests that additional mechanisms may be underlying 
the disruption of neuronal expression of Map2 at later time points. Interestingly, 
at 35-days post-SE Map2 IR levels did not recover beyond the levels seen at 3 
days post-SE. These data further suggest the possibility that a large number of 
viable cells remain in the CA1 area even at 2 weeks post-SE. Furthermore, we 
found that the neuronal marker NeuN was not drastically changed after SE 
(Schartz et al., 2016).  
Prominent microgliosis overlapped with decreased Map2 IR in CA1 sr 
area at 2-3 weeks post SE has been previously reported (Brewster et al., 
2013). In this study we mapped the progression of these events and showed 
that there is considerable spatial and temporal overlap between the SE-
induced loss of Map2 IR and increased microgliosis in the CA1 area. 
Substantial evidence support that microglia undergo inflammatory activation 
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after SE. Releases of a number of inflammatory mediators have been shown to 
contribute to some of the neuropathological changes associated with prolonged 
seizures (Choi & Koh, 2008; Vezzani et al., 2011). We recently confirmed 
neuroinflammation at the acute time points following pilocarpine-induced SE 
(Arisi, Foresti, Katki, & Shapiro, 2015; Benson, Manzanero, & Borges, 2015) 
that correlated with early changes in Map2 levels, but no significant changes in 
inflammatory mediators were observed at the 14 days post-SE time point when 
microgliosis was most prominent (Schartz et al., 2016). In addition to their 
inflammatory properties, microglia are phagocytic cells that clear dead cells 
and cellular debris along with smaller neuronal elements such as synapses 
(Sierra, Abiega, Shahraz, & Neumann, 2013). Thus, the vast accumulation of 
amoeboid microglia with shorter processes in CA1 pcl may be a related to a 
change to a mostly phagocytic phenotype (Kettenmann et al., 2011) which may 
be in response to the increased numbers of apoptotic and dead cells. Thus, it 
is possible that once the dead cells within CA1 have been cleared, microglial 
cells recede from this area over time but not before possibly potentiating 
dendritic alterations in the remaining viable neurons.  
Recent studies show that SE enhances the attraction of microglial 
processes toward neural elements (Eyo et al., 2014) and increases the density 
of cell-to-cell contacts between activated microglia and CA1 dendrites 
(Brewster et al., 2013; Hasegawa et al., 2007). This is important because a 
growing body of evidence supports that microglial cells participate in shaping 
neuronal dendritic architectures and the organization of synaptic connectivity 
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(Paolicelli et al., 2011; Schafer et al., 2012; Tremblay et al., 2011). For 
instance, microglial processes regularly survey their surrounding 
microenvironment making direct contacts with spines and synaptic neuronal 
structures which they can engulf and eliminate (Nimmerjahn, Kirchhoff, & 
Helmchen, 2005; Paolicelli et al., 2011; Schafer et al., 2012; Tremblay et al., 
2011). Thus, based on these data it is conceivable that the vast accumulation 
of microglial cells in CA1 may play a role in the disruption of dendritic 
structures probably by dysregulating Map2 in CA1 neurons.  
Several studies have found an increase in the classical complement 
pathway in neurodegenerative or injury models (Cowell, Plane, & Silverstein, 
2003; Hong et al., 2016; Silverman et al., 2016; Väkevä et al., 1994), and in 
epilepsy models (Aronica et al., 2007). Components of the classical 
complement pathway have also been shown to guide microglia to synapses 
and tag them for phagocytosis (Stevens et al., 2007). Thus, we hypothesized 
that complement proteins may be localized to areas of high microglia 
accumulation and loss of Map2 signal. For this reason, we mapped the 
distribution of C1q and the levels of C3 after SE, focusing on the time points in 
which Map2 and microglial changes were observed (3-35 days post-SE). We 
found an increase in C1q IR at two weeks post-SE that was specific to the CA1 
sr (Fig. 4), which is the dendritic field of CA1 cells. This SE-induced increase in 
C1q IR paralleled that which was observed for the microglial marker IBA1. 
Given that macrophages and micorglia are known to produce and release C1q 
protein (Kettenmann et al., 2013), it is possible that microglia are producing 
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and releasing C1q. This may be underlying the increase in C1q IR seen at two 
weeks post SE. Moreover, we found that the C1q downstream effector C3 was 
cleaved, suggesting activation of C3 as an opsonin and thereby activation of 
the classical complement pathway (Fig. 5). This effect also peaked at 2 weeks 
after SE, matching the time course of C1q, microglia, and Map2 loss.  
The increase in C1q and C3 proteins may result in the opsonization of 
neuronal elements for microglial recognition and targeting for phagocytosis.  
The classical complement pathway has been implicated in guiding microglia to 
pre- and post-synaptic structures during development. Specifically, those 
structures that did not form a connection were tagged by C1q and pruned by 
microglia (Stevens et al., 2007). Similarly, it is possible that dying or vulnerable 
neurons after SE result in uncoupled or weakened synapses that are then 
targeted by C1q for elimination by microglia. Thus, it is possible that due to cell 
death, which peaks at 3 days after SE (Schartz et al., 2016), some synapses 
are left bare or uncoupled (pre- or post-synaptic) and thereby may be tagged 
for elimination. However, this possibility still needs to be investigated. Taken 
together, these findings suggest that the classical complement pathway may 
be guiding microglia to stay within the sr after SE and promoting phagocytosis 
of tagged dendritic structures 
To further understand the role of the classical complement pathway in 
hippocampal histopathological and functional alterations after SE, we used the 
C1-esterase inhibitor to block activation of this pathway immediately following 
SE. We measured downstream effects of complement activation such as 
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microgliosis to determine if treatment with C1-inh could attenuate molecular 
injury and behavioral deficits associated with SE. Because treatment with C1-
inh has been shown to be neuroprotective after injury (Heydenreich et al., 
2012), we expected treatment to be neuroprotective after an episode of SE.  
Surprisingly, C1-inh did not attenuate SE-induced Map2 loss in the 
hippocampus (Fig. 8). Map2 IR did not differ between SE and SE+C1-Inh 
treated rats. An unexpected finding was that treatment with C1-inh actually 
exacerbated microgliosis in the hippocampus, with a significant increase 
observed at 3 days after SE and remaining elevated up to 25 days, whereas 
without the treatment microgliosis peaked at 14 days and fell thereafter (Fig. 
9).Therefore, it is possible that complement activation via the classical pathway 
is neuroprotective immediately after SE. Furthermore, because C1q levels are 
not elevated early on, it is possible that C1-Inh treatment immediately after SE 
affects normal levels of complement activation. Giving C1-Inh treatment to 
sham-treated rats would have provided some insight into the mechanisms 
affected by the drug. However, because of cost, this was not a viable option. 
Future studies will determine the effects of C1-Inh in control animals. 
Treatment with C1-inh has been successful in attenuating injury and 
behavioral deficits in animal models of ischemia and stroke (De Simoni et al., 
2004; De Simoni et al., 2003; Heydenreich et al., 2012), so it was expected to 
reduce cognitive deficits after SE. We first tested SE rats with NOR and BM 
and replicated previous findings (Brewster et al., 2013; Levin et al., 2012; 
Pearson et al., 2014) that following SE, rats exhibit recognition and spatial 
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memory deficits, respectively. Surprisingly, we found that treatment with C1-inh 
did not attenuate memory deficits, and in fact exacerbated the deficits in BM. 
SE rats with C1-Inh treatment performed similarly to SE rats in the NOR test 
(Fig. 11) and performed worse than SE rats in the BM test (Fig. 12), taking 
longer to learn the location of the escape box. It is known that the hippocampus 
is functionally differentiated, with specific regions mediating different types of 
memory. For instance, the dorsal hippocampus is necessary for spatial 
learning (Moser & Moser, 1998). In this study, we compared cellular alterations 
between different regions of the hippocampus (CA1, CA3, DG). However, an 
analysis of the alterations in the dorsal versus ventral hippocampus after SE 
might elucidate more localized effects of SE on the hippocampus and on 
memory. 
In other injury models, C1-inh doses were given between 5 and 90 
minutes after onset of injury, similarly to the time points of drug administration 
in the present study. Increased complement activation in the ischemia model 
has been observed within hours of injury and appears to persist for weeks 
(Silverman et al., 2016; Väkevä et al., 1994), whereas we saw a significant 
increase in C1q and C3 expression only at 2 weeks after SE. Therefore, we 
speculate that adjusting the time point of treatment may still be successful at 
preventing injury after SE if given 10-14 days after the initial episode of SE. 
The time course of treatment was set at 4-48 hours after SE because this is the 
time point in which inflammatory cytokines peaked (Schartz et al., 2016). In 
addition, previous studies using other immunosuppressant drugs have 
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demonstrated that acute treatment can be neuroprotective in models of 
acquired epilepsy (Brewster et al., 2013; Zeng et al., 2009).  
Studies using C1-inh treatment have used intravenous (i.v) injections 
(De Simoni et al., 2003; Emmens et al., 2013; Heydenreich et al., 2012). 
Furthermore, a study compared efficacy of s.c. versus i.v. injections of C1-inh 
by testing serum levels at different time points after injection and found that 
serum levels are much higher and persist longer when given i.v. and that 
serum levels of C1-inh are not different from that of controls (Emmens et al., 
2013). However, the literature is mixed on this topic, with results varying 
depending on the species used (Martinez-Saguer et al., 2014). Given this 
information, perhaps C1-inh treatment could attenuate deficits associated with 
SE if administered intravenously. We will test this possibility in future 
experiments.  
There is also the possibility that C3 cleavage into its biologically active 
peptides C3a and C3b  is the main cause of microgliosis and associated 
dendritic changes after SE. C1-inh acts both on the classical and the lectin 
pathways of the complement system but has no effect on the alternative 
pathway (Nielsen et al., 2007). It is possible that by blocking C1 esterase, 
cleavage of C3 is limited resulting in accumulation of C3. This could then 
trigger the alternative pathway of spontaneous C3 hydrolysis to cleave the C3 
protein. In this case, C3 would still be cleaved into C3a and C3b, which would 
promote increase inflammation and phagocytosis, respectively. Further 
experiments are required to determine if treatment with C1-inh resulted in an 
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increase of C3 cleavage. Based on the behavioral and molecular results of this 
study, it would be expected that C3 activation is increased in the animals 
treated with C1-inh. Previous studies have found that deletion of complement 
component C3 is protective against seizures and results in improved spatial 
memory in models of epilepsy (Libbey et al., 2010; Perez-Alcazar et al., 2014). 
This would suggest that an increase in C3 cleavage may exacerbate the 
seizures and memory deficits in animals that sustained SE and thereby 
activation of the complement cascade may still be a candidate mechanism. In 
future experiments we may inhibit the downstream C3 molecules, which would 
inhibit further activation of all three complement pathways, or use mouse 
knockout models of the C3 ligand and receptors. 
Given the number of recent studies that implicate the complement 
system in inflammatory pathologies it is likely that the complement system is 
involved in the pathology following SE. Moreover, the finding that activation of 
the complement pathway via the classical cascade (C1q and C3) follows the 
pattern of Map2 loss and microgliosis strongly suggests a role for this pathway 
in the remodeling observed.  
Evidence for the spatiotemporal evolution of microgliosis along with the 
complement pathway and their association with other pathological SE-induced 
changes (e.g. dendritic, inflammation, astrogliosis, transcriptional/translational 
dysregulation) in the hippocampus is of importance when evaluating the effects 
of immunosuppressant and anti-inflammatory treatments in models of SE and 
epilepsy. For instance, early vs. late immunosuppressant treatments may lead 
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to different observations likely due to the temporal expression of the drug’s 
targets in microglial cells or within the complement pathway. This may be the 
case underlying the unexpected findings in this study as well as the discrepant 
findings associated with other immunosuppressant treatments (e.g. rapamycin) 
in models of SE and acquired epilepsy (Brewster et al., 2013; Buckmaster & 
Lew, 2011; van Vliet et al., 2012; Zeng et al., 2009). Furthermore, our studies 
may lead to the identification of novel targets within the complement pathway 
to treat epilepsy and its comorbidities.  
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